Kymera Therapeutics Inc
KYMR77.810USD
-0.310-0.40%
Cierre 12/31, 16:00（ET）Cotizaciones retrasadas 15 min
5.58BCap. mercado
PérdidaP/E TTM
Más Datos de Kymera Therapeutics Inc Compañía
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral degrader of IRF5, a genetically validated transcription factor and a master regulator of immunity.
Información de Kymera Therapeutics Inc
Símbolo de cotizaciónKYMR
Nombre de la empresaKymera Therapeutics Inc
Fecha de salida a bolsaAug 21, 2020
Director ejecutivoMainolfi (Nello)
Número de empleados188
Tipo de seguridadOrdinary Share
Fin del año fiscalAug 21
Dirección500 North Beacon Street, 4Th Floor
CiudadWATERTOWN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal02472
Teléfono18572855314
Sitio Webhttps://www.kymeratx.com/
Símbolo de cotizaciónKYMR
Fecha de salida a bolsaAug 21, 2020
Director ejecutivoMainolfi (Nello)
Ejecutivos de Kymera Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
57.49K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Justine Koenigsberg
Ms. Justine Koenigsberg
Vice President - Investor Relations
Vice President - Investor Relations
--
--
Mr. Jeffrey W. (Jeff) Albers, J.D.
Mr. Jeffrey W. (Jeff) Albers, J.D.
Independent Director
Independent Director
--
--
Dr. Bruce L. Booth
Dr. Bruce L. Booth
Independent Chairman of the Board, Co-Founder
Independent Chairman of the Board, Co-Founder
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Nello Mainolfi, Ph.D.
Dr. Nello Mainolfi, Ph.D.
President, Chief Executive Officer, Co-Founder, Director
President, Chief Executive Officer, Co-Founder, Director
659.96K
--
Dr. Jared August Gollob, M.D.
Dr. Jared August Gollob, M.D.
Chief Medical Officer
Chief Medical Officer
57.49K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
52.50K
--
Mr. Noah Goodman
Mr. Noah Goodman
Chief Business Officer
Chief Business Officer
50.08K
--
Dr. Jeremy G. Chadwick, Ph.D.
Dr. Jeremy G. Chadwick, Ph.D.
Chief Operating Officer
Chief Operating Officer
15.80K
-14.01%
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2024
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
47.07M
0.00%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 30 de nov
Actualizado: dom., 30 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
13.36%
Avoro Capital Advisors LLC
7.96%
Fidelity Management & Research Company LLC
7.37%
BVF Partners L.P.
6.90%
The Vanguard Group, Inc.
6.78%
Otro
57.63%
Accionistas
Accionistas
Proporción
Baker Bros. Advisors LP
13.36%
Avoro Capital Advisors LLC
7.96%
Fidelity Management & Research Company LLC
7.37%
BVF Partners L.P.
6.90%
The Vanguard Group, Inc.
6.78%
Otro
57.63%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
40.05%
Hedge Fund
28.83%
Investment Advisor/Hedge Fund
28.22%
Venture Capital
7.47%
Individual Investor
1.29%
Research Firm
1.28%
Corporation
0.97%
Private Equity
0.51%
Bank and Trust
0.39%
Participación institucional
Actualizado: hace 2 horas
Actualizado: hace 2 horas
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
446
85.54M
107.20%
+2.78M
2025Q3
423
80.49M
111.88%
+1.59M
2025Q2
394
76.16M
108.56%
+417.04K
2025Q1
408
74.79M
106.76%
-4.90M
2024Q4
392
73.17M
112.73%
-3.17M
2024Q3
379
71.17M
110.57%
-5.78M
2024Q2
360
69.86M
113.52%
-7.55M
2024Q1
364
70.22M
115.13%
-982.70K
2023Q4
350
63.05M
113.62%
-5.46M
2023Q3
341
59.94M
108.11%
-9.64M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Baker Bros. Advisors LP
10.66M
13.36%
+4.01M
+60.31%
Dec 11, 2025
Avoro Capital Advisors LLC
6.35M
7.96%
-205.56K
-3.14%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.88M
7.37%
+447.08K
+8.23%
Sep 30, 2025
BVF Partners L.P.
5.50M
6.9%
--
--
Dec 11, 2025
The Vanguard Group, Inc.
5.41M
6.78%
-198.13K
-3.53%
Sep 30, 2025
Wellington Management Company, LLP
5.20M
6.51%
-176.37K
-3.28%
Sep 30, 2025
T. Rowe Price Associates, Inc.
5.04M
6.31%
-1.77M
-25.96%
Sep 30, 2025
Atlas Venture
4.90M
6.14%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
3.72M
4.67%
+205.15K
+5.83%
Sep 30, 2025
Invus Public Equities Advisors, LLC
3.43M
4.3%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Clough Hedged Equity ETF
2.42%
Invesco Dorsey Wright Healthcare Momentum ETF
1.41%
Harbor Human Capital Factor US Small Cap ETF
1.31%
State Street SPDR S&P Biotech ETF
1.27%
Virtus LifeSci Biotech Clinical Trials ETF
0.89%
Direxion Daily S&P Biotech Bull 3X Shares
0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
0.61%
ProShares Ultra Nasdaq Biotechnology
0.59%
Invesco Nasdaq Biotechnology ETF
0.43%
First Trust Small Cap Growth AlphaDEX Fund
0.35%
Ver más
Clough Hedged Equity ETF
Proporción2.42%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporción1.41%
Harbor Human Capital Factor US Small Cap ETF
Proporción1.31%
State Street SPDR S&P Biotech ETF
Proporción1.27%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.89%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.63%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporción0.61%
ProShares Ultra Nasdaq Biotechnology
Proporción0.59%
Invesco Nasdaq Biotechnology ETF
Proporción0.43%
First Trust Small Cap Growth AlphaDEX Fund
Proporción0.35%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Kymera Therapeutics Inc?
Los cinco principales accionistas de Kymera Therapeutics Inc son:
Baker Bros. Advisors LP posee 10.66M acciones, lo que representa el 13.36% del total de acciones.
Avoro Capital Advisors LLC posee 6.35M acciones, lo que representa el 7.96% del total de acciones.
Fidelity Management & Research Company LLC posee 5.88M acciones, lo que representa el 7.37% del total de acciones.
BVF Partners L.P. posee 5.50M acciones, lo que representa el 6.90% del total de acciones.
The Vanguard Group, Inc. posee 5.41M acciones, lo que representa el 6.78% del total de acciones.
Baker Bros. Advisors LP posee 10.66M acciones, lo que representa el 13.36% del total de acciones.
Avoro Capital Advisors LLC posee 6.35M acciones, lo que representa el 7.96% del total de acciones.
Fidelity Management & Research Company LLC posee 5.88M acciones, lo que representa el 7.37% del total de acciones.
BVF Partners L.P. posee 5.50M acciones, lo que representa el 6.90% del total de acciones.
The Vanguard Group, Inc. posee 5.41M acciones, lo que representa el 6.78% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Kymera Therapeutics Inc?
Los tres principales tipos de accionista de Kymera Therapeutics Inc son:
Baker Bros. Advisors LP
Avoro Capital Advisors LLC
Fidelity Management & Research Company LLC
Baker Bros. Advisors LP
Avoro Capital Advisors LLC
Fidelity Management & Research Company LLC
¿Cuántas instituciones poseen acciones de Kymera Therapeutics Inc (KYMR)?
A fecha de 2025Q4, 446 instituciones poseen acciones de Kymera Therapeutics Inc, con un valor de mercado combinado de aproximadamente 85.54M, lo que representa el 107.20% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -4.68%.
¿Cuál es la mayor fuente de ganancias de Kymera Therapeutics Inc?
El FY2024, el segmento empresarial -- generó la ganancia más alta para Kymera Therapeutics Inc, ascendiendo a -- y representando el --% de la ganancia total.
